Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 152 No. 0910 (2022)

Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis

  • Sophie Kasmi
  • Florent Artru
  • Joana Vieira Barbosa
  • Ansgar Rudolf Deibel
  • Lucie Favre
  • Claire Peuble
  • Anne-Catherine Saouli
  • Nicolas Goossens
  • Beat Müllhaupt
  • Manuel Pascual
  • Darius Moradpour
  • Julien Vionnet
  • Montserrat Fraga
DOI
https://doi.org/10.4414/SMW.2022.w30138
Cite this as:
Swiss Med Wkly. 2022;152:w30138
Published
01.03.2022

Summary

BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is now the first cause of chronic liver disease in developed countries. We aimed to assess trends in the prevalence of obesity, type 2 diabetes mellitus (T2DM) and NAFLD in patients undergoing liver transplantation evaluation and to assess whether obese patients were less likely to be listed or had an increased drop-out rate after listing.

METHODS: We conducted a retrospective study of all consecutive patients who underwent liver transplantation evaluation at a Swiss tertiary referral centre between January 2009 and March 2020.

RESULTS: A total of 242 patients were included, 83% were male. The median age was 59 years (IQR, 51–64 years). The most common causes of end-stage liver disease were viral hepatitis (28%), alcoholic liver disease (21%) and NAFLD (12%). Obesity was present in 28% of our cohort, with a significant increase over time. Prevalence of type 2 diabetes mellitus followed the same trend (p = 0.02). The proportions of non-listed and listed obese patients did not differ (21% vs. 30% respectively; p = 0.3).

CONCLUSIONS: The prevalence of obesity and type 2 diabetes mellitus significantly increased over our study period. Obese patients had similar chances of being listed. The landscape of liver transplantation indications is shifting towards NAFLD, highlighting the urgent need to prevent NAFLD progression.

References

  1. Seidell JC, Halberstadt J. The global burden of obesity and the challenges of prevention. Ann Nutr Metab. 2015;66 Suppl 2:7–12. https://doi.org/10.1159/000375143
  2. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019 Dec;381(25):2440–50. https://doi.org/10.1056/NEJMsa1909301
  3. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med. 2006 Jan;12(1):62–6. https://doi.org/10.1038/nm0106-62
  4. Friedman AN, Miskulin DC, Rosenberg IH, Levey AS. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003 Feb;41(2):480–7. https://doi.org/10.1053/ajkd.2003.50059
  5. Parikh ND, Marrero WJ, Wang J, Steuer J, Tapper EB, Konerman M, et al. Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology. 2019 Aug;70(2):487–95. https://doi.org/10.1002/hep.29473
  6. Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, et al.; all the contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018 Oct;69(4):810–7. https://doi.org/10.1016/j.jhep.2018.06.010
  7. Cholankeril G, Ahmed A. Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2018 Aug;16(8):1356–8. https://doi.org/10.1016/j.cgh.2017.11.045
  8. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan;67(1):328–57. https://doi.org/10.1002/hep.29367
  9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998 Jul;15(7):539–53. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
  10. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002 Apr;346(16):1221–31. https://doi.org/10.1056/NEJMra011775
  11. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73–84. https://doi.org/10.1002/hep.28431
  12. Terrault NA, Pageaux GP. A changing landscape of liver transplantation: king HCV is dethroned, ALD and NAFLD take over! J Hepatol. 2018 Oct;69(4):767–8. https://doi.org/10.1016/j.jhep.2018.07.020
  13. Axley P, Ahmed Z, Arora S, Haas A, Kuo YF, Kamath PS, et al. NASH Is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the United States: A population-based study. Liver Transpl. 2019 May;25(5):695–705. https://doi.org/10.1002/lt.25443
  14. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, et al.; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019 Mar;17(4):748–755.e3. https://doi.org/10.1016/j.cgh.2018.05.057
  15. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr;348(17):1625–38. https://doi.org/10.1056/NEJMoa021423
  16. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012 Jun;56(6):1384–91. https://doi.org/10.1016/j.jhep.2011.10.027
  17. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009 Mar;49(3):851–9. https://doi.org/10.1002/hep.22734
  18. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010 Sep;363(14):1341–50. https://doi.org/10.1056/NEJMra0912063
  19. Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014 Mar;59(3):1144–65. https://doi.org/10.1002/hep.26972
  20. Kardashian AA, Dodge JL, Roberts J, Brandman D. Weighing the risks: morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. Liver Int. 2018 Mar;38(3):553–63. https://doi.org/10.1111/liv.13523
  21. Kaur N, Emamaullee J, Lian T, Lo M, Ender P, Kahn J, et al. Impact of Morbid Obesity on liver transplant candidacy and outcomes: national and regional trends. Transplantation. 2021 May;105(5):1052–60. https://doi.org/10.1097/TP.0000000000003404
  22. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: liver transplantation. J Hepatol. 2016 Feb;64(2):433–85. https://doi.org/10.1016/j.jhep.2015.10.006
  23. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al.; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019
  24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct;112(17):2735–52. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
  25. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388–402. https://doi.org/10.1016/j.jhep.2015.11.004
  26. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S186–90. https://doi.org/10.1046/j.1440-1746.17.s1.10.x
  27. Goossens N, Bellentani S, Cerny A, Dufour JF, Jornayvaz FR, Mertens J, et al. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030. Swiss Med Wkly. 2019 Dec;149:w20152. https://doi.org/10.4414/smw.2019.20152
  28. Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2021 Mar;19(3):580–589.e5. https://doi.org/10.1016/j.cgh.2020.05.064
  29. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020 Jul;73(1):202–9. https://doi.org/10.1016/j.jhep.2020.03.039
  30. Csige I, Ujvárosy D, Szabó Z, Lőrincz I, Paragh G, Harangi M, et al. The impact of obesity on the cardiovascular system. J Diabetes Res. 2018 Nov;2018:3407306. https://doi.org/10.1155/2018/3407306
  31. Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013 Jan;19(1):3–26. https://doi.org/10.1002/lt.23566
  32. Phelan SM, Burgess DJ, Yeazel MW, Hellerstedt WL, Griffin JM, van Ryn M. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes Rev. 2015 Apr;16(4):319–26. https://doi.org/10.1111/obr.12266
  33. Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharmacol Ther. 2020 Jan;51(1):64–77. https://doi.org/10.1111/apt.15571
  34. Ri M, Aikou S, Seto Y. Obesity as a surgical risk factor. Ann Gastroenterol Surg. 2017 Oct;2(1):13–21. https://doi.org/10.1002/ags3.12049
  35. Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, et al.; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol. 2019 Aug;71(2):313–22. https://doi.org/10.1016/j.jhep.2019.04.011
  36. Swisstransplant - Annual figures [Internet]. Available from: https://www.swisstransplant.org/en
  37. Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149(2):379-388-16.
  38. Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020 Oct;159(4):1290–1301.e5. https://doi.org/10.1053/j.gastro.2020.06.006
  39. Diwan TS, Rice TC, Heimbach JK, Schauer DP. Liver transplantation and bariatric surgery: timing and outcomes. Liver Transpl. 2018 Sep;24(9):1280–7. https://doi.org/10.1002/lt.25303

Most read articles by the same author(s)

1 2 3 > >>